

## Publishing options: CRKN associated corresponding authors



## 1. Key definitions

Terminology	Definition
Submitting corresponding author	Submitting corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey  This is the author who makes the publishing choice on behalf of the author group
	Every article has one corresponding author
Acceptance Date	This is the date the journal accepts the article for publication
Elsevier OA Platform	Elsevier OA Platform (EOAP) is a user-friendly interface where we present the institutional administrators with the open access articles eligible for the agreement.  Administrators at the institution validate the eligibility of the author for an OA agreement
Gold Open Access	The final version of the published journal article is made freely available, immediately, to everyone. An author can publish Gold Open Access in an open access journal OR in a Hybrid journal which offers open access



## 2. Eligibility criteria

Eligibility component	Description
Acceptance date	The acceptance date of the article should fall within the period of agreement for your institution
Author affiliation	The submitting corresponding author must be affiliated with a participating institution in the agreement.
Journal title	The article must be submitted to and accepted in a participating journal.
APC available	Institution has APCs for the year



### Publishing options after acceptance



#### Finalize Publishing your Article

**Corresponding author** 

acceptance with a

unique link to complete the author

journey and choose publishing options

**Author clicks on Complete the Rights** 

and Access information form

 $\wedge$ Corresponding author E-mail address International Journal of Pharmaceutics Journal Article number 121624 Our reference IJP\_121624 S0378-5173(22)00179-X PII receives an email post Welcome To help us finalize the publication of your article please complete the publishing form(s) below. Note: you will receive a confirmation e-mail after completing each form. information you may need to provide to complete the forms Rights and Access Complete the rights and access form > Help and Support How you can share your article Author rights information A guide to publishing Open Access




Corresponding author

E-mail address

Corresponding author selects his/her affiliation details which we use to identify the authors and match them to CRKN agreement


Please note that the author has already provided this information at submission; it is

prepopulated






Corresponding author also adds the co-author affiliation details





Author can add the Funder details.
Funder can be the affiliated institution or a different one. In this case it is Milliman



Previous

Save and Continue >

- Based on the affiliation details, the author sees the Publishing Options.
   Gold OA option is followed by Subscription option, and we inform the author that agreement covers the APC
- If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice
- Author selects Gold OA

#### Gold Open Access

O Publish as an Open Access article

Make my published article available to everyone.

As a corresponding author affiliated with the Brandon University, upon validation, the agreement between the Canadian Research Knowledge Network (CRKN) and Elsevier  $\supset$  will cover the APC.

I and others can share and reuse my article in the ways described by the user license I select.

#### Article Publishing Charge (APC)

Price

usd 4,190.00

Institutional Agreement Discount



- 4,190.00

To pay (on validation)



0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,190.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model.

Brandon University and Elsevier Agreement


#### Subscription

O Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of Elsevier's programs .


I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined here  $\supset$ .

Previous Save and Continue >





#### **Author selects the rights**





## System presents author with the Journal License Publishing Agreement

#### Your Status

I am one author signing on behalf of all co-authors of the manuscript

#### License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Elsevier B.V.

V

#### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

#### Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

#### Author agrees to the Journal License Publishing Agreement

For further information see the publishing ethics page at https://www.elsevier.com/about/our-business/policies/publishing-ethics and the journal home page. For further information on sanctions, see https://www.elsevier.com/about/our-business/policies/trade-sanctions

#### Author representations

- published.

  The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other
  - journal.

. The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously

- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of
  any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by
  applicable law and complied with the publisher's policies relating to the use of such images or personal information. See
  https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

#### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright ¬.

I have read and agree to the terms of the License Agreement.

17 December 2021 T-copyright license-v5/2017

Home

Finish >


Help

#### Rights and Access



Previous

- Corresponding author and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Librarian/admin at the institution will receive a notification for validation within 48 hours who then has 3 weeks to validate the request
- If the Librarian/admin approves the request, the author will receive the full APC coverage
- If the Librarian/admin rejects the request, the author will receive the full price invoice



#### Support for authors and librarians/admins

- Author queries <u>oasupport@elsevier.com</u>
- Librarian/Admin queries, EOAP account set up or changes agreementactivation@elsevier.com
- Author journey videos:
   <a href="https://service.elsevier.com/app/answers/detail/a\_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP\_X\_/">https://service.elsevier.com/app/answers/detail/a\_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP\_X\_/</a>





# Thank you

